Advanced Therapy Medicinal Products Cdmo Market Report: Market Size & Forecast 2026

The ATMP CDMO market provides end-to-end development and manufacturing services for advanced therapeutic products that are based on genes, cells, or tissue engineering. These services span process development, clinical and commercial manufacturing, quality control, regulatory support, and fill-finish operations for products that often require personalized or specialized production approaches. The market has emerged as a critical component of the biopharmaceutical supply chain as the complexity of ATMP manufacturing exceeds the capabilities of many drug developers.

The expanding clinical pipeline of cell and gene therapies is the primary engine of market growth, with hundreds of therapies in development targeting oncology, rare diseases, and other indications. Pharmaceutical companies are increasingly turning to CDMOs to avoid the enormous capital investment required to build specialized ATMP manufacturing facilities, particularly those capable of handling viral vectors and autologous cell therapies. Additionally, regulatory support for advanced therapies and breakthrough designations has accelerated clinical development timelines, increasing demand for flexible manufacturing capacity.

The market is segmented by product type, with cell therapy and gene therapy representing the largest and fastest-growing segments, followed by tissue-engineered products and other ATMP categories. Services are also categorized by development phase, including preclinical, clinical (Phase I-III), and commercial manufacturing support. Geographically, North America currently leads the market due to the concentration of biotechnology companies, strong FDA support for advanced therapies, and significant R&D investment, while Europe maintains a substantial share and the Asia-Pacific region is growing rapidly as local capabilities expand.

What are the recent trends and outlook?

The market is moving toward more flexible and scalable manufacturing solutions, including modular and portable cleanroom technologies that can support multiple product types and enable decentralized manufacturing closer to treatment centers. Continued innovation in viral vector production, closed automated systems, and process intensification is expected to improve manufacturing efficiency and reduce costs. Over the forecast period through 2031, the market is projected to sustain strong growth fueled by increasing demand for advanced therapies and expanding CDMO capacity globally.